克里唑蒂尼
间变性淋巴瘤激酶
铈替尼
阿列克替尼
肺癌
医学
碱性抑制剂
肿瘤科
癌症研究
内科学
恶性胸腔积液
出处
期刊:PubMed
日期:2024-03-23
卷期号:46 (3): 189-205
标识
DOI:10.3760/cma.j.cn112152-20230901-00110
摘要
Anaplastic lymphoma kinase (ALK) fusion gene is one of the most common driver gene in non-small cell lung cancer (NSCLC). Epidemiological data showed that ALK gene fusion is detected in 9.06% of Chinese advanced NSCLC patients. ALK-tyrosine kinase inhibitors (TKIs) have become the standard treatment for advanced NSCLC patients with ALK gene fusion. Seven different ALK-TKIs have been approved by the National Medical Products Administration (NMPA) of China, including crizotinib, ceritinib, alectinib, ensartinib, brigatinib, lorlatinib, and iruplinalkib. Iruplinalkib is a novel new-generation ALK-TKI independently developed in China. On June 27, 2023, the NMPA approved iruplinalkib for the treatment of locally advanced or metastatic ALK-positive NSCLC patients whose disease has progressed after previous treatment with crizotinib or who are intolerant to crizotinib. On January 16, 2024, the NMPA approved iruplinalkib for the first-line treatment of locally advanced or metastatic ALK-positive NSCLC patients. In order to better understand the efficacy and safety of iruplinalkib, and facilitate more rationally clinical application of iruplinalkib, the Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care and the Chinese Association for Clinical Oncologists co-organized experts to compile the "Chinese expert consensus on iruplinalkib for the treatment of locally advanced or metastatic ALK-positive non-small cell lung cancer (2024 edition)".间变性淋巴瘤激酶(ALK)融合基因是非小细胞肺癌(NSCLC)常见的驱动基因之一。流行病学数据显示,在中国晚期NSCLC患者中ALK融合基因的阳性率为9.06%。ALK酪氨酸激酶抑制剂(TKIs)已经成为ALK融合基因阳性晚期NSCLC患者的标准治疗选择。目前中国国家药品监督管理局已经批准7种ALK-TKIs上市,分别是克唑替尼、塞瑞替尼、阿来替尼、恩沙替尼、布格替尼、洛拉替尼和伊鲁阿克。伊鲁阿克是中国自主研发的新型ALK-TKI,2023年6月27日,国家药品监督管理局批准伊鲁阿克上市,用于既往接受过克唑替尼治疗后疾病进展或对克唑替尼不耐受的ALK融合基因阳性局部晚期或转移性NSCLC患者的治疗,2024年1月16日,国家药品监督管理局批准伊鲁阿克用于ALK融合基因阳性局部晚期或转移性NSCLC患者的一线治疗。为了帮助广大医师更好地了解伊鲁阿克的疗效和安全性,使伊鲁阿克得到更合理的临床应用,中国医疗保健国际交流促进会肿瘤内科学分会和中国医师协会肿瘤医师分会组织专家编写了《伊鲁阿克治疗间变性淋巴瘤激酶融合基因阳性局部晚期或转移性非小细胞肺癌中国专家共识(2024版)》。.
科研通智能强力驱动
Strongly Powered by AbleSci AI